Coya Therapeutics (COYA) announced the appointment of Arun Swaminathan to the role of chief business officer. In this role, Arun will be responsible for facilitating new business development partnerships, including in/out licensing opportunities, across the company’s pipeline. Prior to joining Coya, Swaminathan served as chief business officer for Actinium Pharmaceuticals (ATNM) where he was responsible for all business development including out-licensing, in-licensing and other creative value generating options.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on COYA:
- Chardan bullish on Coya following ‘encouraging’ data for 302 targeting ALS
- Coya Therapeutics reports data from COYA 302 study
- Coya Therapeutics enters worldwide COYA 302 agreement with Dr. Reddy’s
- Meet Coya Therapeutics: Fly exclusive interview with CEO Howard Berman
- David Einhorn’s Greenlight Makes Changes to the Hedge Fund Positions